32 results about "Synaptic protein" patented technology

A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.

The invention discloses a traditional Chinese medicine composition, a preparation method and application thereof. The traditional Chinese medicine composition is composed of Coptidis Rhizoma Cortex Phellodendron, Cortex Phellodendri, Gardenia, Salvia Miltiorrhiza, Curcuma longa and Shichangpu. The traditional Chinese medicine composition can significantly improve the learning and memory dysfunction of 5×FAD transgenic mice, reduce the expression of Aβ40 / 42 in the hippocampus, and increase the 5 The expression levels of pre- and post-synaptic proteins in the hippocampus of ×FAD transgenic mice can improve the excitatory synaptic transmission disorder in the hippocampus of 5×FAD mice, and at the same time inhibit the apoptosis of hippocampal neurons and the proliferation of microglia in 5×FAD mice In addition, it can inhibit the expression of inflammatory factors in the serum and hippocampus of 5×FAD mice, which provides a reliable theoretical basis for the preparation of drugs for the treatment or adjuvant treatment of Alzheimer's disease.

The invention discloses a recombinant Tau epitope chimeric polymer antigen as well as a preparation method and an application thereof. The invention provides the recombinant Tau epitope chimeric polymer antigen, which is a basic unit of 6 or 12 tandem phosphatase activation domains of Tau protein and two helper T cell epitopes Th. The recombinant 6 / 12*(Tau2-18-Th) chimeric antigen disclosed by theinvention can generate a high-level Th2 type anti-Tau2-18 antibody after being used for immunizing common and model mice in a low-dose and few-time manner, T cell immune response aiming at Tau2-18 isnot generated, the pathological level of A beta (including soluble oligomers) and Tau (including total Tau and phosphorylated Tau) in the brain of the mouse model is reduced, the related synaptic protein level is increased, and the learning and memory ability is improved. Therefore, a recombinant chimeric epitope vaccine targeting Tau2-18 is a new direction of AD novel vaccine research, which hasgreat potential and application prospect in prevention of Alzheimer's disease.

The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.

The invention belongs to the technical field of marine organisms, and relates to a preparation process of spirulina protein and its neuroprotective application. Specifically, the invention discloses a preparation method of spirulina protein. The spirulina powder is soaked, freeze-thawed, salted out, dialyzed and freeze-dried to obtain the spirulina protein. The spirulina protein provided by the present invention can reduce the survival rate of the nerve cell strain PC-12 under oxidative damage, reduce the aggregation of the toxic protein α-synuclein of the Parkinson's disease model nematode strain NL5901, and inhibit the Huntington's disease model Caenorhabditis elegans (AM141 ) can alleviate the neurotoxicity caused by Aβ toxic protein in the Alzheimer's disease model Caenorhabditis elegans (CL2355), and has neuroprotective function.

The invention relates to identification of synaptogyrin-3 as a target for treating or inhibiting progression of tauopathies or symptoms of tauopathies. In particular, synaptogyrin-3 inhibitors for use as a medicament in general, and for treating or inhibiting progression of tauopathies or symptoms of tauopathies are envisaged. The invention further relates to methods for identification of or for screening for inhibitors of synaptogyrin-3.

A molecular construct comprises a donor label, an acceptor label, a linker peptide disposed between the donor and the acceptor, the linker having a cleavage site sequence, and a spacer between at least one of (a) the donor and the cleavage site sequence and (b) the acceptor and the cleavage site sequence. Preferably, the construct is selected from the group consisting of CFP-(SGLRSRA)-SNAP-25-(SNS)-YFP, and CFP-(SGLRSRA)-synaptobrevin-(SNS)-YFP. In preferred embodiments, the linker peptide is a substrate of a botulinum neurotoxin selected from the group consisting of synaptobrevin (VAMP), syntaxin and SNAP-25, or a fragment thereof that can be recognized and cleaved by the botulinum neurotoxin. Advantageously, the spacer increases the electronic coupling between the donor label and the acceptor label relative to a corresponding construct without the spacer.